Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT: 2012-2024

Historic EBT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $195.2 million.

  • Amphastar Pharmaceuticals' EBT fell 54.88% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year decrease of 28.64%. This contributed to the annual value of $195.2 million for FY2024, which is 7.29% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EBT stood at $195.2 million for FY2024, which was up 7.29% from $181.9 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year EBT high stood at $195.2 million for FY2024, and its period low was $4.6 million during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' EBT averaged around $168.1 million, with its median value being $181.9 million (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBT tumbled by 93.99% in 2020, and later spiked by 1,714.51% in 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBT (Yearly) stood at $4.6 million in 2020, then skyrocketed by 1,714.51% to $84.1 million in 2021, then surged by 51.18% to $127.2 million in 2022, then soared by 43.02% to $181.9 million in 2023, then increased by 7.29% to $195.2 million in 2024.